tbuckley/cabot-search huggingface dataset:
Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization
Authors: Ambarish Pandey, Kershaw V. Patel, Li Liang, Adam D. DeVore, Roland Matsouaka, Deepak L. Bhatt, Clyde W. Yancy, Adrian F. Hernandez, Paul A. Heidenreich, James A. de Lemos, Gregg C. Fonarow
Journal: JAMA Cardiology (2018)

Among patients hospitalized with heart failure (HF), the long-term clinical implications of hospitalization at hospitals based on 30-day risk-standardized mortality rates (RSMRs) is not known.To evaluate the association of hospital-specific 30-day RSMR with long-term survival among patients hospitalized with HF in the American Heart Association Get With The Guidelines-HF registry.The longitudinal observational study included 106 304 patients with HF who were admitted to 317 centers participating in the Get With The Guidelines-HF registry from January 1, 2005, to December 31, 2013, and had Medicare-linked follow-up data. Hospital-specific 30-day RSMR was calculated using a hierarchical logistic regression model. In the model, 30-day mortality rate was a binary outcome, patient baseline characteristics were included as covariates, and the hospitals were treated as random effects. The association of 30-day RSMR-based hospital groups (low to high 30-day RSMR: quartile 1 [Q1] to Q4) with long-term (1-year, 3-year, and 5-year) mortality was assessed using adjusted Cox models. Data analysis took place from June 29, 2017, to February 19, 2018.Thirty-day RSMR for participating hospitals.One-year, 3-year, and 5-year mortality rates.Of the 106 304 patients included in the analysis, 57 552 (54.1%) were women and 84 595 (79.6%) were white, and the median (interquartile range) age was 81 (74-87) years. The 30-day RSMR ranged from 8.6% (Q1) to 10.7% (Q4). Hospitals in the low 30-day RSMR group had greater availability of advanced HF therapies, cardiac surgery, and percutaneous coronary interventions. In the primary landmarked analyses among 30-day survivors, there was a graded inverse association between 30-day RSMR and long-term mortality (Q1 vs Q4: 5-year mortality, 73.7% vs 76.8%). In adjusted analysis, patients admitted to hospitals in the high 30-day RSMR group had 14% (95% CI, 10-18) higher relative hazards of 5-year mortality compared with those admitted to hospitals in the low 30-day RSMR group. Similar findings were observed in analyses of survival from admission, with 22% (95% CI, 18-26) higher relative hazards of 5-year mortality for patients admitted to Q4 vs Q1 hospitals.Lower hospital-level 30-day RSMR is associated with greater 1-year, 3-year, and 5-year survival for patients with HF. These differences in 30-day survival continued to accrue beyond 30 days and persisted long term, suggesting that 30-day RSMR may be a useful HF performance metric to incentivize quality care and improve long-term outcomes.
Theoretical and practical facial soft tissue course
Authors: Roger Stevens
Journal: BMJ (2008)

This one day theoretical and practical facial soft tissue course is organised by Leo Cheng, who is a consultant in oral and maxillofacial surgery at Barts and The London NHS Trust and the Homerton University Hospital NHS Foundation Trust and a volunteer surgeon on board the Mercy Ships in west Africa. He is assisted by several of his consultant colleagues.

The course is designed to provide junior trainees with a theoretical background and practical training in handling facial soft tissue. It is most suitable for trainees in oral and maxillofacial surgery; plastic surgery; ear, nose, and throat surgery; and emergency medicine.

The morning consists of highly informative lectures about the theory …
Training for Lung Ultrasound Score Measurement in Critically Ill Patients
Authors: Jean-Jacques Rouby, Charlotte Arbelot, Yuzhi Gao, Mao Zhang, Jie Lv, Youzhong An, Wang Chunyao, Du Bin, Carmen Silvia Valente Barbas, Felippe Leopoldo Dexheimer Neto, Fabiola Prior Caltabeloti, Emidio Lima, Andres Cebey, Sébastien Perbet, Jean-Michel Constantin, Charlotte Arbelot, Jean-Jacques Rouby, Hélène Brisson, Romain Deransy, Corinne Vezinet, Pierre Garçon, Nabil El Hadj Kacem, Denis Lemesle, Antoine Monsel, Qin Lu, Olivier Langeron, Frédérick Gay, Bruno Lucena, Luiz Malbouisson, Maria José Carvalho Carmona, Julio Neves, Paulo de Tarso Roth Dalcin, Guilherme de Paula Pinto Schettino, Alberto Biestro, Davi Cristovao, Jorge Salluh
Journal: American Journal of Respiratory and Critical Care Medicine (2018)

than 5 ml/kg PBW, mean EFFi increased from 0.722 to 0.736, or by 1.8 6 0.8% (mean 6 SD).The exact value chosen for VANA appears not to be critical.Therefore, a moderate error in flow sensor calibration is of low importance.In future studies, EFFi should be compared with alternative parameters (e.g., VAE/VT proposed by Lucangelo and colleagues [10]).Because EFFi and VDphys/VT reflect uneven V : /Q : among lung compartments, it was expected that they correlate closely.EFFi is easier to study, as it is noninvasive and may be continuously monitored.The study is limited to small groups.However, at health, the results show a low degree of variation, as expected from absence of variability caused by disease.The total separation between health and ARDS indicates that, in mechanically ventilated patients, EFFi may be useful for monitoring of ARDS evolution.This aspect is strengthened by the fact that EFFi may automatically, continuously, and noninvasively be monitored in the individual patient, who then serves as his own standard of reference.EFFi merits further studies in broad materials covering ARDS and other diseases, performed with modern capnographic equipment.
Fluorogen-activating proteins: beyond classical fluorescent proteins
Authors: Shengnan Xu, Hai-Yu Hu
Journal: Acta Pharmaceutica Sinica B (2018)

Fluorescence imaging is a powerful technique for the real-time noninvasive monitoring of protein dynamics. Recently, fluorogen activating proteins (FAPs)/fluorogen probes for protein imaging were developed. Unlike the traditional fluorescent proteins (FPs), FAPs do not fluoresce unless bound to their specific small-molecule fluorogens. When using FAPs/fluorogen probes, a washing step is not required for the removal of free probes from the cells, thus allowing rapid and specific detection of proteins in living cells with high signal-to-noise ratio. Furthermore, with different fluorogens, living cell multi-color proteins labeling system was developed. In this review, we describe about the discovery of FAPs, the design strategy of FAP fluorogens, the application of the FAP technology and the advances of FAP technology in protein labeling systems.
Gray-Brown Patches on the Face of a 62-Year-Old Woman
Authors: Yul W. Yang, Steven A. Nelson, Shari A. Ochoa
Journal: JAMA Dermatology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Abstract P006: Cardiovascular Disease Risk Factor Burden is Associated With Hearing Loss in Young Men: The Hispanic Community Health Study/Study of Latinos
Authors: Rachael R Baiduc, Brittany Bogle, Franklyn Gonzalez, Elizabeth Dinces, David J Lee, Martha Daviglus, Sumitrajit Dhar, Jianwen Cai
Journal: Circulation (2018)

Introduction: Over 30 million Americans suffer from hearing loss (HL). Studies suggest that established cardiovascular disease (CVD) risk factors may contribute to the pathophysiology of the inner ear. However, the aggregate effect of CVD risk factors on hearing is not well understood. Hypothesis: We hypothesized that high CVD risk burden is associated with worse hearing. Methods: We assessed younger (ages 18-34) and older (ages 55-64) Hispanic Community Health Study / Study of Latinos participants who underwent audiometry in 2008-11. After excluding those with conductive pathology and asymmetric HL, we randomly chose one ear for analysis. Puretone thresholds were obtained at 0.5-8 kHz; puretone average (PTA) was calculated using thresholds at 0.5, 1, 2, and 4 kHz. Low CVD risk burden was defined as having all of: blood pressure (BP) &lt;120/&lt;80 mmHg; total cholesterol &lt;180 mg/dL; not currently smoking; and not having prevalent diabetes. High CVD risk burden was defined as ≥ 2 of: diabetes; currently smoking; BP &gt;160/&gt;100 mmHg (or antihypertensive use); and total cholesterol &gt;240 mg/dL (or statin use). By age group and sex, we estimated hearing thresholds per frequency with linear regression models adjusted for noise exposure. Least squares estimates were calculated using strata-specific means of covariates. Estimates were compared via t-tests. Data were weighted for all analyses and accounted for clustering. Results: Among younger and older individuals in the target population (51.9% female), 28.8% had low and 5.5% had high CVD risk. Younger men with high CVD risk had worse PTA than young men with low risk (7.7 dB HL [7.0-8.4] vs. 10.5 dB HL [8.4-12.5], p =0.02), and had significantly worse thresholds at 1,3,4,6 kHz than those with low risk ( Figure ). There was no difference in PTA or thresholds at any frequency by CVD risk burden in young women, older men, or older women. Conclusions: CVD risk burden is associated with HL among young men, but not young women or older adults. CVD risk burden may be useful for identifying young men at risk for HL.
Effect of A1C and Glucose on Postoperative Mortality in Noncardiac and Cardiac Surgeries
Authors: Willem van den Boom, Rebecca A. Schroeder, Michael W. Manning, Tracy L. Setji, Gic-Owens Fiestan, David B. Dunson
Journal: Diabetes Care (2018)

OBJECTIVE Hemoglobin A1c (A1C) is used in assessment of patients for elective surgeries because hyperglycemia increases risk of adverse events. However, the interplay of A1C, glucose, and surgical outcomes remains unclarified, with often only two of these three factors considered simultaneously. We assessed the association of preoperative A1C with perioperative glucose control and their relationship with 30-day mortality. RESEARCH DESIGN AND METHODS Retrospective analysis on 431,480 surgeries within the Duke University Health System determined the association of preoperative A1C with perioperative glucose (averaged over the first 3 postoperative days) and 30-day mortality among 6,684 noncardiac and 6,393 cardiac surgeries with A1C and glucose measurements. A generalized additive model was used, enabling nonlinear relationships. RESULTS A1C and glucose were strongly associated. Glucose and mortality were positively associated for noncardiac cases: 1.0% mortality at mean glucose of 100 mg/dL and 1.6% at mean glucose of 200 mg/dL. For cardiac procedures, there was a striking U-shaped relationship between glucose and mortality, ranging from 4.5% at 100 mg/dL to a nadir of 1.5% at 140 mg/dL and rising again to 6.9% at 200 mg/dL. A1C and 30-day mortality were not associated when controlling for glucose in noncardiac or cardiac procedures. CONCLUSIONS Although A1C is positively associated with perioperative glucose, it is not associated with increased 30-day mortality after controlling for glucose. Perioperative glucose predicts 30-day mortality, linearly in noncardiac and nonlinearly in cardiac procedures. This confirms that perioperative glucose control is related to surgical outcomes but that A1C, reflecting antecedent glycemia, is a less useful predictor.
Metastatic Carcinoid Tumour in Association with Small Bowel Ischaemia and Infarction
Authors: J J Payne-James, C J de Gara, D Lovell, J J Misiewicz, N Menzies Gow
Journal: Journal of the Royal Society of Medicine (1990)

Case reports Case 1: Routine investigations ofa 63-year-old woman with abdominal pain and weight loss were inconclusive. At laparotomy the peritoneum was studded with multiple tumour deposits. No primary was identified. The deposits were metastatic carcinoid tumour. Urinary 5 hydroxyindoleacetic acid (5HIAA) was normal. Twelve days postoperatively she developed severe abdominal pain, guarding and absent bowel sounds. At laparotomy the small bowel excluding the proximal 80 cm of jejunum was ischaemic. No mechanical or other cause for the ischaemia was evident. Resection and primary anastomosis was undertaken. There was evidence ofthrombosis, embolus or vasculitis. Twentyfour months after the second laparotomy she remains well with no clinical evidence of disease progression.
EVALUATION OF BURDEN OF RHEUMATIC HEART DISEASE AMONG SCHOOL CHILDREN IN NORTH-WEST INDIA BY ECHOCARDIOGRAPHY USING WORLD HEART FEDERATION CRITERIA: A PRELIMINARY REPORT
Authors: Rajababu Panwar, Balkrishna Gupta, Dinesh Chaudhary, Sadik Panwar
Journal: Journal of the American College of Cardiology (2018)
Abstract 18826: Excellent Outcomes in Long-Term Follow-Up After Heart Transplantation for Cardiac Sarcoidosis
Authors: David G Rosenthal, Molly E Anderson, Bradley J Petek, Daniel M Arnett, Zachary D Goldberger, Kristen K Patton, Richard K Cheng
Journal: Circulation (2016)

Introduction: Orthotopic heart transplant (OHT) is increasingly utilized for end-stage heart failure due to cardiac sarcoidosis (CS). However, concern regarding the long-term outcomes in CS patient...
Abstract 15135: The Cardioprotective Effect of the Modern Farmed Atlantic Salmon -Dietary Spillover from Fish
Authors: Annette Bernhard, Josef D Rasinger, Lisa K Midtbø, Lene S Myrmel, Bente E Torstensen, Karsten Kristiansen, Lise Madsen, Trond Brattelid
Journal: Circulation (2014)

Introduction:  Omega-3 (n-3) long-chain polyunsaturated fatty acids (PUFAs) and in particular DHA and EPA from oily fish have beneficial cardiovascular effects. To meet the demands for sustainability and reduce production cost parts of the marine ingredients in the “modern” Atlantic salmon diet have been replaced by vegetable oil (VO) increasing the monoene fatty acid levels and to some extent the linoleic and linolenic fatty acids on the expense of n-3 PUFAS in the filet. The nutritional as well as cardio protective benefit of the modern farmed Atlantic salmon is therefore under discussion.   Hypothesis:  Filets of salmon fed VO with a reduced n-3/n-6 ratio has reduced anti atherosclerotic properties compared to filets of salmon fed FO.   Methods:  Fillets of Atlantic salmon fed diets with fish oil (FO) or diets where FO was partly replaced (80%) with rapeseed (RO) or soy oil (SO) were used to prepare western style diets high in fat, sucrose and cholesterol for use in a mouse trial. Three groups of male apoE knock out (KO) mice were fed either of the three western style diets with FO (n=14; alpha-linolenic acid (ALA) level: 1.6 mg/g), SO (n=13; ALA: 2.6 mg/g) or RO (n=13; ALA: 4.0 mg/g) salmon replacing 50% of the dietary protein.   Results:  Replacement of FO with SO and RO in the salmon diet led to a significant accumulation of fat in mice livers. Higher red blood cell n-6 levels were detected in SO (1.40 ± 0.18 mg/g) and RO (1.16 ± 0.08 mg/g) fed mice when compared to the FO (0.68 ± 0.05 mg/g) fed groups. Interestingly the HDL cholesterol was higher in RO and SO whereas the LDL cholesterol was high in SO when compared to FO. Despite these metabolic changes, atherosclerotic lesion were reduced in the arch and abdominal region in RO (12 ± 1% and 4 ± 1% respectively) fed mice compared to the FO (18 ± 2% and 10 ± 2% respectively) fed mice.   Conclusions:  The dietary spillover from salmon fed VO induced systemic metabolic changes, but also cardio protection in apoE KO mice fed a diet with filets from RO fed salmon. The level of ALA in RO and its potential anti atherosclerotic effect warrants further investigation.
Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer (BTC).
Authors: Changqing Xie, Suzanne Fioravanti, Melissa Walker, Donna Mabry, David E Kleiner, Brad J. Wood, Elliot B Levy, Venkatesh P Krishnasamy, Seth M. Steinberg, Austin G. Duffy, Tim F. Greten
Journal: Journal of Clinical Oncology (2018)

365 Background: Treatment option for patients with advanced BTC is limited and prognosis is poor with a median survival of less than 1 year in the locally advanced or metastatic setting. It has been shown deregulation of the immune system plays an important role in the pathogenesis of BTC. This study aimed to investigate whether tremelimumab (Treme), anti-CTLA4, could be combined safely and feasibly with microwave ablation therapy to enhance the effect of anti-CTLA4 treatment in patients with advanced BTC. Methods: Patients with refractory BTC were enrolled in a study of monthly Treme (10mg/kg, IV, 6 doses), followed by 3-monthly infusions until off-treatment criteria were met. On day 36, patients underwent subtotal microwave ablation. Staging image was performed every 8 weeks. Adverse events (AEs) were collected and managed. Tumor samples and peripheral blood samples were collected to perform immune monitoring. Results: Twenty patients with refractory BTC were enrolled. Male: female ratio was 10:10 with median age 56.5 years (range 37-67). Six patients had extrahepatic cholangiocarcinoma (ECC), two patients had gallbladder cancer, whereas the remaining 12 patients had intrahepatic cholangiocarcinoma (ICC). No dose-limiting toxicities were encountered. The common AEs included lymphocytopenia, colitis, adrenal insufficiency, anemia, and elevated transaminases. The most common clinical toxicity was diarrhea. Sixteen patients were evaluable for response analysis, one (6%) patient achieved a confirmed partial response (lasting for 8 months), 6 (37.5%) achieved stable disease with the longest lasting for 9.2 months. Among all 20 patients, median progression free survival, time to progression, and overall survival were 3.4 months (95% CI 2.5-5.2 months), 3.3 months (95% CI: 2.5-4.6 months) and 6.0 months (95% CI 3.8-8.8 months) respectively in this small pilot cohort. T cell receptor (TCR) b screening showed Treme expanded TCR repertoire though non-significantly. RNA seq is ongoing and will be presented. Conclusions: Treme in combination with tumor ablation is a potential new treatment for patients with advanced BTC. TCR repertoire expansion induced by Treme may contribute to treatment benefit. Clinical trial information: NCT01853618.
Phase I open label trial of intraperitoneal paclitaxel (IPP) in combination with intravenous cisplatin (C) and oral capecitabine (X) in patients with advanced gastric cancer and peritoneal metastases.
Authors: Sina Vatandoust, Tim I. Bright, Amitesh Chandra Roy, Myron Klevansky, Jeff Bull, Christos Stelios Karapetis
Journal: Journal of Clinical Oncology (2018)

TPS201 Background: There have been few studies investigating advanced gastric cancer with peritoneal involvement and ascites, showing poor survival in these patients. Researchers from Japan have shown that chemotherapy with IPP and Oral S-1 (tegafur/gimeracil/oteracil) is active in these patients. These results have been achieved in a different genetic pool (Japanese population) compared with Australia, using regimens that are not available here. We have designed this phase I trial to investigate the Maximum Tolerated Dose (MDT) of IPP in combination with a standard chemotherapy combination (C+X) in these patients. Methods: This is an open-label, single centre, phase I trial with 3+3 expanded cohort design. Patients will have an IP catheter placed surgically after trial enrolment. Study was approved by the relevant ethics committee. Chemotherapy: maximum of six 21-day cycles of: X (PO, 1000 mg/m2 BD days 1-14) + C (IV 80mg/m2 day 1) + IPP (day 1 and 8) with the following doses: Cohort-1: 10 mg/m2, Cohort-2: 20 mg/m2 and Cohort-3: 30 mg/m2. Important inclusion criteria: age ≥ 18 years, signed written informed consent, HER-2 non-amplified gastric adenocarcinoma with biopsy or cytology showing peritoneal involvement and/or ascites, adequate organ function and signed consent. Important exclusion criteria: history of another malignancy within 5 years, life expectancy &lt; 3months, peripheral neuropathy, recent ( &lt; 4 weeks) abdominal or pelvic radiation treatment, significant intra-abdominal adhesions or active intra-abdominal sepsis. Cohorts 1 and 2 have been completed. Enrolment to cohort-3 is beginning in October 2017. Clinical trial information: ACTRN12614001063606.
A New Frontier in Curing Corneal Blindness
Authors: Reza Dana
Journal: New England Journal of Medicine (2018)

What was very likely the first allogeneic corneal transplantation took place in the 1830s, when the Irish surgeon Samuel Bigger performed the procedure on a blinded gazelle's eye.1 Then, in 1905, nearly half a century before the first successful kidney transplantation, the Austrian surgeon Eduard Zirm successfully transplanted a corneal allograft in a patient. Corneal grafting is currently the most common form of transplantation, with well over 100,000 procedures performed annually worldwide.2 Of these procedures, close to half are performed to replace the corneal endothelium, a monolayer of cells that has the primary function of transporting fluid to enable the . . .
Scientists Separate Opioids’ Analgesic Effects From Their Dangerous Respiratory Effects
Authors: Tracy Hampton
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal